Visitors Now:
Total Visits:
Total Stories:
Profile image
Story Views

Now:
Last Hour:
Last 24 Hours:
Total:

Global LAG-3 Antagonists, TIM-3 Antagonists & OX40 Agonists Market Research Report 2016

Tuesday, November 15, 2016 22:59
% of readers think this story is Fact. Add your two cents.

(Before It's News)

“Global LAG-3 Antagonists, TIM-3 Antagonists & OX40 Agonists-Pipeline Insights, 2016”

DelveInsight’s, “LAG-3 Antagonists, TIM-3 Antagonists & OX40 Agonists-Pipeline Insights, 2016”, report provides comprehensive insight and understanding for all the pipeline drugs that fall under LAG-3 Antagonists, TIM-3 Antagonists & OX40 Agonists. With the emerging immune-oncology therapeutic strategy for T-cell-mediated diseases, companies are focusing on the development of immune-check inhibitors like Lag-3, OX-40 and TIM-3 inhibitors which gained importance in recent years. 

Report highlights that majorly development is seen for Lag-3 antagonist, with the lead drug of Prima BioMed in Phase II stage of development. In case of OX-40 agonists close to 4 drugs are in Phase I stage of development with AstraZeneca having its 2 drug candidates in Phase I. Majorly drug candidates are seen in early stages of development for LAG-3 Antagonists, TIM-3 Antagonists & OX40 Agonists. 

Try Sample Report @ https://www.wiseguyreports.com/sample-request/476533-lag-3-antagonists-tim-3-antagonists-ox40-agonists-pipeline-insights-2016

The Report gives insights on 33+ products with 20+ different technologies. The Report also provides LAG-3 Antagonists, TIM-3 Antagonists & OX40 Agonists related therapeutic assessments by molecule type, route of administration, monotherapy and combination products. 

Scope 
• DelveInsight’s report provides a LAG-3 Antagonists, TIM-3 Antagonists & OX40 Agonists Landscape across the globe 
• The report provides drug profiles which includes product description, MOA, licensors & collaborators, technology, development partner and chemical information 
• Coverage of the LAG-3 Antagonists, TIM-3 Antagonists & OX40 Agonists pipeline on the basis of target, MOA, route of administration, technology involved and molecule type 
• The report reviews key players involved in the therapeutics development for LAG-3 Antagonists, TIM-3 Antagonists & OX40 Agonists and also provide company profiling 
• Pipeline products coverage based on various stages of development from NDA filings to discovery. 
• Provides pipeline assessment by monotherapy and combination therapy products, stage of development and molecule type.

Access Complete Report @ https://www.wiseguyreports.com/reports/476533-lag-3-antagonists-tim-3-antagonists-ox40-agonists-pipeline-insights-2016

Reason to Buy

  • Complete Pipeline intelligence and complete understanding over therapeutics development for LAG-3 Antagonists, TIM-3 Antagonists & OX40 Agonists 
    § Identify different type of technologies involved in the development of the therapeutics. 
    § Identify the relationship between the drugs and use it for target finding, drug repurposing, and precision medicine. 
    § Track your competitors and develop strategic initiatives to support your drug development activities. 
    § Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline 
    § Devise corrective measures for pipeline projects by understanding LAG-3 Antagonists, TIM-3 Antagonists & OX40 Agonists pipeline in-depth 
    § Understand the market and choose right partners for in-licensing and out licensing for your valuable assets

Table of contents: 
LAG-3, TIM-3 & OX40 Overview 
Total Products Overview 
Products Share by Clinical Stages 
Products Share by Pre-clinical and Discovery Stages 
LAG-3 Antagonists 
Pipeline Therapeutics 
Therapeutics under Development by Companies 
Mid Stage Products (Phase II) 
Comparative Analysis 
Early Stage Products (Phase I and IND) 
Comparative Analysis 
Discovery and Pre-clinical stage Products 
Comparative Analysis 
Therapeutic Assessment 
Assessment by Monotherapy Products 
Assessment by Combination Products 
Assessment by Route of Administration 
Assessment by Molecule Type 
TIM-3 Antagonists 
Pipeline Therapeutics 
Therapeutics under Development by Companies 
Early Stage Products (Phase I and IND) 
Comparative Analysis 
Discovery and Pre-clinical stage Products 
Comparative Analysis 
Therapeutic Assessment 
Assessment by Monotherapy Products 
Assessment by Combination Products 
Assessment by Route of Administration 
Assessment by Molecule Type 
OX40 Agonists 
Pipeline Therapeutics 
Therapeutics under Development by Companies 
Early Stage Products (Phase I and IND) 
Comparative Analysis 
Discovery and Pre-clinical stage Products 
Comparative Analysis 
Therapeutic Assessment 
Assessment by Monotherapy Products 
Assessment by Route of Administration 
Assessment by Molecule Type 
Additional Information 
Discontinued Products 
Companies Involved in Therapeutics Development 
Methodology 
Consulting Services 
About DelveInsight 
Contact Us 
Disclaimer

List of tables 
Table 1: Total Products for LAG-3 Antagonists, TIM-3 Antagonists and OX-40 Agonists, 2016 
Table 2: Share of Products for LAG-3 Antagonists, TIM-3 Antagonists and OX-40 Agonists in Clinical Stages, 2016 
Table 3: Share of Products for LAG-3 Antagonists, TIM-3 Antagonists and OX-40 Agonists in Pre-clinical and Discovery, 2016 
Table 4: Number of Products under Development for LAG-3 Antagonists, 2016 
Table 5: Number of Products under Development by Companies, 2016 
Table 6: Mid Stage Products (Phase II), 2016 
Table 7: Early Stage Products (Phase I and IND), 2016 
Table 8: Discovery and Pre-clinical Stage Products, 2016 
Table 9: Assessment by Monotherapy Products for LAG-3 Antagonists, 2016 
Table 10: Assessment by Combination Products for LAG-3 Antagonists, 2016 
Table 11: Assessment by Route of Administration for LAG-3 Antagonists, 2016 
Table 12: Assessment by Stage and Route of Administration for LAG-3 Antagonists, 2016 
Table 13: Assessment by Molecule Type for LAG-3 Antagonists, 2016 
Table 14: Assessment by Stage and Molecule Type for LAG-3 Antagonists, 2016 
Table 15: Number of Products under Development for TIM-3 Antagonists, 2016 
Table 16: Number of Products under Development by Companies, 2016 
Table 17: Early Stage Products (Phase I and IND), 2016 
Table 18: Discovery and Pre-clinical Stage Products, 2016 
Table 19: Assessment by Monotherapy Products for TIM-3 Antagonists, 2016 
Table 20: Assessment by Route of Administration for TIM-3 Antagonists, 2016 
Table 21: Assessment by Stage and Route of Administration for LAG-3 Antagonists, 2016 
Table 22: Assessment by Molecule Type for TIM-3 Antagonists, 2016 
Table 23: Assessment by Stage and Molecule Type for TIM-3 Antagonists, 2016 
Table 24: Number of Products under Development for OX40 Agonists, 2016 
Table 25: Number of Products under Development by Companies, 2016 
Table 26: Early Stage Products (Phase I and IND), 2016 
Table 27: Discovery and Pre-clinical Stage Products, 2016 
Table 28: Assessment by Monotherapy Products for OX40 Agonists, 2016 
Table 29: Assessment by Route of Administration for OX40 Agonists, 2016 
Table 30: Assessment by Stage and Route of Administration for OX40 Agonists, 2016 
Table 31: Assessment by Molecule Type for OX40 Agonists, 2016 
Table 32: Assessment by Stage and Molecule Type for OX40 Agonists, 2016 
Table 33: Discontinued Products, 2016 
Table 34: Companies Involved in Therapeutic Development, 2016

Buy Report @ https://www.wiseguyreports.com/checkout?currency=one_user-USD&report_id=476533

For more information or any query mail at sales@wiseguyreports.com

Contact Us:
Norah Trent
+1 646 845 9349 / +44 208 133 9349
Follow on LinkedIn: 
https://www.linkedin.com/company/wise-guy-research-consultants-pvt-ltd-?trk=biz-companies-cym

Report abuse

Comments

Your Comments
Question   Razz  Sad   Evil  Exclaim  Smile  Redface  Biggrin  Surprised  Eek   Confused   Cool  LOL   Mad   Twisted  Rolleyes   Wink  Idea  Arrow  Neutral  Cry   Mr. Green

Top Stories
Recent Stories

Register

Newsletter

Email this story
Email this story

If you really want to ban this commenter, please write down the reason:

If you really want to disable all recommended stories, click on OK button. After that, you will be redirect to your options page.